


CADTH delivers timely, evidence-based information to health care decision-makers about the effectiveness and efficiency of pharmaceuticals, medical devices, diagnostics, and procedures.

## Reports and Recommendations




CADTH provides credible, objective evidence to its customers through a variety of product types.

### Completed Reviews (522 Total)



### Reimbursement Recommendations Issued (63 Total)



CDR = CADTH Common Drug Review; pCODR = CADTH pan-Canadian Oncology Drug Review.


reports and recommendations

## Access



CADTH's numerous outreach services and its search-based website help disseminate evidence to those who need it most.


### Knowledge Events (111 Total)



CADTH reported more than **4,470 participants** (71% increase from last year) at **111 knowledge events**:


Our post-knowledge event surveys revealed **80% of participants** reported an increase in knowledge about the related topic.

### Implementation Tools (108 Total)



access

### Website Metrics



### Top Five Downloaded Reports\*

- 01** *Low Dose Naltrexone for the Treatment of Any Cancer Type: Clinical Effectiveness and Guidelines* (Rapid Response)
- 02** *One Dose of Doxycycline for the Prevention of Lyme Disease: A Review of Clinical Effectiveness and Guidelines* (Rapid Response)
- 03** *Medical Cannabis for the Treatment of Chronic Pain: A Review of Clinical Effectiveness and Guidelines* (Rapid Response)
- 04** *Utilization of Innovator Biologics and Biosimilars for Chronic Inflammatory Diseases in Canada: A Provincial Perspective* (Technology Review)
- 05** *Community Water Fluoridation Programs: A Health Technology Assessment* (Technology Review)

\*This ranking does not include Drug Reimbursement Reviews reports

access

## Impact



CADTH is making meaningful contributions to a modern and sustainable health care system in Canada.

### Drug Reimbursement Recommendation Outcomes

Of 32 pCODR reimbursement recommendations made during the 2019–2020 fiscal year:

Positive or Conditional: **23**

Negative: **09**


Of 31 CDR reimbursement recommendations made during the 2019–2020 fiscal year:

Positive or Conditional: **25**

Negative: **06**


access

### Timeline of Drug Reimbursement Recommendations




### Alignment of Reimbursement Recommendations With Listing Decisions

The consistency with which jurisdictions align their drug plan listing decisions with CADTH's reimbursement recommendations (past 36 months):



### pCPA Negotiation Status of CADTH Reimbursement Recommendations



### Impact Stories

Overall, CADTH recorded **78 impact stories** for the 2019–2020 fiscal year:



### Samples of CADTH's Impact Across the Country

- National**  
According to survey results, CADTH's Optimal Use Report entitled *Internet-Delivered Cognitive Behavioural Therapy (iCBT) for Major Depression and Anxiety Disorders in Canada* was used across seven jurisdictions, and 55% of survey respondents used the report to inform a decision (clinical practice change, change in policy, a coverage decision, or a significant change in service delivery or process).  
Excellent content, there is a great deal of interest in virtual care and so it is very useful to be able to access real-world experience and evidence. — Survey respondent  
Excellent report due to the use of multiple data sources. Reading made a person think of the many factors that can impact treatment outcomes. — Survey respondent  
Correctional Services Canada undertook a review of nabilone. In November 2019, a decision was made to expand its criteria based on the evidence CADTH provided.
- Northern**  
In Yukon, docusate was removed from gynecology post-operative orders due in part to the CADTH Rapid Response report.
- Western**  
Alberta Health Services is working to implement a practice change related to the use of N-acetylcysteine in mucolysis. N-acetylcysteine was used when prescribed, but an alternative and more evidence-based approach was developed using CADTH Rapid Response requests.
- Eastern**  
The Government of Newfoundland and Labrador announced in December 2019 that it was lifting the maximum dose caps for anti-vascular endothelial growth factor medication under the Newfoundland and Labrador Prescription Drug Program. This policy decision was informed by a preliminary search for evidence, a Rapid Response report, a CADTH Briefing Note, Questions and Answers document, and a stakeholder presentation.

impact


## Patient and Clinician Engagement



CADTH implemented the CADTH Patient and Community Advisory Committee and continued its clinician engagement strategy to increase clinician awareness of CADTH, enhance clinician engagement, and influence clinical practice.

### Events

CADTH has delivered several large **jurisdictional events** that have engaged a broad range of customers and stakeholders, including clinicians, on various topics such as:



### Awareness Strategy

- 006** Six new **opioid tools** developed to inform and guide patients, clinicians, and policy-makers.
- 008** **Webinars and events** hosted for northern territorial groups during the 2019–2020 fiscal year.
- 001** Created a **Clinical Liaison Officer** position to provide oversight and coordination of clinician engagement.
- 012** Implemented the **CADTH Patient and Community Advisory Committee**, consisting of 12 members.
- 100+** **More than 100 tools and evidence reports** on pain management and substance use have been completed and posted to our evidence bundles.

ABOUT CADTH  
CADTH is an independent, not-for-profit organization responsible for providing Canada's health care decision-makers with objective evidence to help make informed decisions about the optimal use of drugs and medical devices in our health care system.  
CADTH receives funding from Canada's federal, provincial, and territorial governments, with the exception of Quebec.  
December 2020